174 related articles for article (PubMed ID: 38350338)
1. Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.
Geurts YM; Neppelenbroek SIM; Aleman BMP; Janus CPM; Krol ADG; van Spronsen DJ; Plattel WJ; Roesink JM; Verschueren KMS; Zijlstra JM; Koene HR; Nijziel MR; Schimmel EC; de Jongh E; Ong F; Te Boome LCJ; van Rijn RS; Böhmer LH; Ta BDP; Visser HPJ; Posthuma EFM; Bilgin YM; Muller K; van Kampen D; So-Osman C; Vermaat JSP; de Weijer RJ; Kersten MJ; van Leeuwen FE; Schaapveld M
ESMO Open; 2024 Feb; 9(2):102248. PubMed ID: 38350338
[TBL] [Abstract][Full Text] [Related]
2. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.
van den Belt-Dusebout AW; de Wit R; Gietema JA; Horenblas S; Louwman MW; Ribot JG; Hoekstra HJ; Ouwens GM; Aleman BM; van Leeuwen FE
J Clin Oncol; 2007 Oct; 25(28):4370-8. PubMed ID: 17906202
[TBL] [Abstract][Full Text] [Related]
3. Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis.
Jiang S; Zhen H; Jiang H
Curr Probl Cancer; 2020 Feb; 44(1):100502. PubMed ID: 31537411
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
Teepen JC; van Leeuwen FE; Tissing WJ; van Dulmen-den Broeder E; van den Heuvel-Eibrink MM; van der Pal HJ; Loonen JJ; Bresters D; Versluys B; Neggers SJCMM; Jaspers MWM; Hauptmann M; van der Heiden-van der Loo M; Visser O; Kremer LCM; Ronckers CM;
J Clin Oncol; 2017 Jul; 35(20):2288-2298. PubMed ID: 28530852
[TBL] [Abstract][Full Text] [Related]
5. The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
Yin X; Xu A; Huang Z; Fan F; Wang Y; Chen L; Cui G; Hu Y; Sun C
Transl Oncol; 2021 Jul; 14(7):101106. PubMed ID: 33932917
[TBL] [Abstract][Full Text] [Related]
6. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
Tao L; Clarke CA; Rosenberg AS; Advani RH; Jonas BA; Flowers CR; Keegan THM
Br J Haematol; 2017 Jul; 178(1):72-80. PubMed ID: 28542862
[TBL] [Abstract][Full Text] [Related]
7. Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors.
De Sanctis V; Alfò M; Di Rocco A; Ansuinelli M; Russo E; Osti MF; Valeriani M; Minniti G; Grapulin L; Musio D; Bracci S; Spagnoli A; Moleti ML; Tombolini V; Martelli M
Hematol Oncol; 2017 Dec; 35(4):554-560. PubMed ID: 28078727
[TBL] [Abstract][Full Text] [Related]
8. Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen.
Neeman Y; Perry C; Silverman B; Waintraub N; Avivi I
Leuk Lymphoma; 2020 Nov; 61(11):2638-2644. PubMed ID: 32611210
[TBL] [Abstract][Full Text] [Related]
9. Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe.
Bright CJ; Hawkins MM; Winter DL; Alessi D; Allodji RS; Bagnasco F; Bárdi E; Bautz A; Byrne J; Feijen EAM; Fidler MM; Garwicz S; Grabow D; Gudmundsdottir T; Guha J; Haddy N; Jankovic M; Kaatsch P; Kaiser M; Kuehni CE; Linge H; Øfstaas H; Ronckers CM; Skinner R; Teepen JC; Terenziani M; Vu-Bezin G; Wesenberg F; Wiebe T; Sacerdote C; Jakab Z; Haupt R; Lähteenmäki P; Zaletel LZ; Kuonen R; Winther JF; de Vathaire F; Kremer LC; Hjorth L; Reulen RC;
J Natl Cancer Inst; 2018 Jun; 110(6):649-660. PubMed ID: 29165710
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort.
Turcotte LM; Liu Q; Yasui Y; Henderson TO; Gibson TM; Leisenring W; Arnold MA; Howell RM; Green DM; Armstrong GT; Robison LL; Neglia JP
J Clin Oncol; 2019 Dec; 37(34):3310-3319. PubMed ID: 31622130
[TBL] [Abstract][Full Text] [Related]
11. Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era.
Groot HJ; Lubberts S; de Wit R; Witjes JA; Kerst JM; de Jong IJ; Groenewegen G; van den Eertwegh AJM; Poortmans PM; Klümpen HJ; van den Berg HA; Smilde TJ; Vanneste BGL; Aarts MJ; Incrocci L; van den Bergh ACM; Jóźwiak K; van den Belt-Dusebout AW; Horenblas S; Gietema JA; van Leeuwen FE; Schaapveld M
J Clin Oncol; 2018 Aug; 36(24):2504-2513. PubMed ID: 29989856
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
13. Risk of Subsequent Neoplasms During the Fifth and Sixth Decades of Life in the Childhood Cancer Survivor Study Cohort.
Turcotte LM; Whitton JA; Friedman DL; Hammond S; Armstrong GT; Leisenring W; Robison LL; Neglia JP
J Clin Oncol; 2015 Nov; 33(31):3568-75. PubMed ID: 26261260
[TBL] [Abstract][Full Text] [Related]
14. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer.
Reulen RC; Frobisher C; Winter DL; Kelly J; Lancashire ER; Stiller CA; Pritchard-Jones K; Jenkinson HC; Hawkins MM;
JAMA; 2011 Jun; 305(22):2311-9. PubMed ID: 21642683
[TBL] [Abstract][Full Text] [Related]
15. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.
Marees T; Moll AC; Imhof SM; de Boer MR; Ringens PJ; van Leeuwen FE
J Natl Cancer Inst; 2008 Dec; 100(24):1771-9. PubMed ID: 19066271
[TBL] [Abstract][Full Text] [Related]
16. Risk of a second malignant neoplasm among 5-year survivors of cancer in childhood and adolescence in British Columbia, Canada.
MacArthur AC; Spinelli JJ; Rogers PC; Goddard KJ; Phillips N; McBride ML
Pediatr Blood Cancer; 2007 Apr; 48(4):453-9. PubMed ID: 16767718
[TBL] [Abstract][Full Text] [Related]
17. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study.
Neglia JP; Friedman DL; Yasui Y; Mertens AC; Hammond S; Stovall M; Donaldson SS; Meadows AT; Robison LL
J Natl Cancer Inst; 2001 Apr; 93(8):618-29. PubMed ID: 11309438
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of second malignant neoplasms in adolescents and young adults with cancer.
Lee JS; DuBois SG; Coccia PF; Bleyer A; Olin RL; Goldsby RE
Cancer; 2016 Jan; 122(1):116-23. PubMed ID: 26441212
[TBL] [Abstract][Full Text] [Related]
19. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
20. Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup.
Allodji RS; Hawkins MM; Bright CJ; Fidler-Benaoudia MM; Winter DL; Alessi D; Fresneau B; Journy N; Morsellino V; Bárdi E; Bautz A; Byrne J; Feijen ELA; Teepen JC; Vu-Bezin G; Rubino C; Garwicz S; Grabow D; Gudmundsdottir T; Guha J; Hau EM; Jankovic M; Kaatsch P; Kaiser M; Linge H; Muraca M; Llanas D; Veres C; Øfstaas H; Diallo I; Mansouri I; Ronckers CM; Skinner R; Terenziani M; Wesenberg F; Wiebe T; Sacerdote C; Jakab Z; Haupt R; Lähteenmäki P; Zaletel LZ; Kuehni CE; Winther JF; Michel G; Kremer LCM; Hjorth L; Haddy N; de Vathaire F; Reulen RC
Eur J Cancer; 2019 Aug; 117():71-83. PubMed ID: 31260818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
